



ASX Announcement

For immediate release

9 December 2019

CSL Appoints New Non Executive-Director

CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that Ms Carolyn Hewson AO has been appointed as an independent Non-Executive Director, effective immediately.

Ms Carolyn Hewson AO

Ms Hewson has over 35 years' experience in the finance sector. Ms Hewson brings extensive financial market, risk and investment management experience to the CSL Board.

Ms Hewson has previously held long-term Non-Executive roles in a number of sectors, having held director appointments with Schroders Australia Limited, Stockland Group, BT Investment Management Limited, Westpac Banking Corporation, AGL Energy Limited, the Australian Gas Light Company, CSR Limited, AMP Limited, South Australian Water and the Economic Development Board of South Australia.

Ms Hewson recently retired as a Non-executive Director of BHP Limited where she was Chairman of the BHP Remuneration Committee and a member of the Nomination and Governance Committee. She remains a Director of Infrastructure SA and a Member of the Federal Government Growth Centres Advisory Committee.

Ms Hewson is an Australian resident, with a long-standing involvement in the not-for-profit sector, having being made an Officer of the Order of Australia in 2009 for her services to the broader community and to business.

CSL Chairman Dr Brian McNamee said, "I'm delighted to welcome Carolyn to the CSL Board and look forward to working with her. Carolyn's notable experience in strategy development, capital management and deep understanding of organisational culture will be extremely valuable to the expertise mix of the Board".



ASX Announcement

About CSL

CSL (ASX:CSL) is a leading global biotechnology company with a dynamic portfolio of life-saving medicines, including those that treat haemophilia and immune deficiencies, as well as vaccines to prevent influenza. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL — including our two businesses, CSL Behring and Seqirus - provides life-saving products to more than 70 countries and employs 25,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest.

Authorised for lodgement by:

Fiona Mead
Company Secretary

For further information, please contact:

Media:

Jemimah Brennan
Head of Asia Pacific Corporate Affairs
Telephone: +61 412 635 483
Email: Jemimah.Brennan@csl.com.au

Investors:

Mark Dehring
Head of Investor Relations
Telephone: +61 3 9389 3407
Email: mark.dehring@csl.com.au